Sampling the multiple folding mechanisms of Trp-cage in explicit solvent

Jarek Juraszek, Peter G. Bolhuis

Proceedings of the National Academy of Sciences

Explicit SolventEngineeringProtein AssemblyProtein FoldingMolecular Self-assembly +12

A common solution to group 2 influenza virus neutralization

Robert H. Friesen, Peter S. Lee, Esther J. M. Stoop, +20

Proceedings of the National Academy of Sciences

VaccinationCr8020 EpitopeVaccine TargetImmunologyMolecular Biology +11

Stabilizing the closed SARS-CoV-2 spike trimer

Jarek Juraszek, Lucy Rutten, Sven Blokland, +6

Nature Communications

Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization

Boerries Brandenburg, Wouter Koudstaal, Jaap Goudsmit, +10

PLoS ONE

VaccinationHuman Immune SystemImmunologyViral PathogenesisAntiviral Response +8

Potent peptidic fusion inhibitors of influenza virus

Rameshwar U. Kadam, Jarek Juraszek, Boerries Brandenburg, +13

Science

Peptide EngineeringMolecular BiologyPeptide TherapeuticsAntiviral DrugViral Structural Protein +16

A small-molecule fusion inhibitor of influenza virus is orally active in mice

Maria J. P. van Dongen, Rameshwar U. Kadam, Jarek Juraszek, +29

Science

VaccinationBnab FunctionalityInfluenza VirusMedicineImmunology +13

Rate Constant and Reaction Coordinate of Trp-Cage Folding in Explicit Water

Jarek Juraszek, Peter G. Bolhuis

Biophysical Journal

Trp-cage FoldingExplicit WaterSurface TensionRate ConstantPhysical Chemistry +4

Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling

Corentin Herbert, Ulrich Schieborr, Krishna Saxena, +22

Cancer Cell

Molecular PharmacologySignal TransductionSignaling PathwayG Protein-coupled ReceptorFgf Receptor +9

Predicting the reaction coordinates of millisecond light-induced conformational changes in photoactive yellow protein

Jocelyne Vreede, Jarek Juraszek, Peter G. Bolhuis

Proceedings of the National Academy of Sciences

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff, +285

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine Testing +5